Pablo J. Cagnoni - 01 Feb 2023 Form 4 Insider Report for Rubius Therapeutics, Inc.

Role: Director
Signature: /s/ Jennifer Kamocsay, attorney-in-fact
Issuer symbol: N/A
Transactions as of: 01 Feb 2023
Net transactions value: -$2,112
Form type: 4
Filing time: 01 Feb 2023, 20:41:05 UTC
Previous filing: 31 Jan 2023
Next filing: 21 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RUBY	Common Stock	Sale	$2,112	-8,448	-11%	$0.2500^*	66,082	01 Feb 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.

Content

Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units for the Reporting Person, as previously disclosed on a Form 4 filed with the Securities and Exchange Commission on January 31, 2023. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the reporting person.